Moderna-Merck mRNA Cancer Vaccine Shows 49 Percent Risk Reduction in Phase 3 Melanoma Trial, Biotech Stocks Surge

💡 A Breakthrough for mRNA Therapeutics

Moderna and Merck announced on May 11, 2026 that their investigational personalized mRNA cancer vaccine, mRNA-4157 (also designated V940), in combination with Merck's Keytruda (pembrolizumab), reduced the risk of recurrence or death by 49% compared to Keytruda alone in an interim analysis of the Phase 3 INTerpath-002 trial in high-risk Stage III/IV melanoma patients following complete surgical resection.

The study enrolled 1,089 patients across 25 countries. At a median follow-up of 34 months, 78.6% of patients in the combination arm remained recurrence-free versus 62.5% in the Keytruda monotherapy arm (hazard ratio = 0.51; p < 0.0001). The companies have submitted the data to the FDA and European Medicines Agency for regulatory review, and both agencies have granted Breakthrough Therapy Designation and PRIME scheme status respectively, indicating an expedited review timeline.

mRNA-4157 is a fully personalized vaccine: after surgical removal of a patient's tumor, genomic sequencing identifies up to 34 patient-specific neoantigens (mutated proteins unique to the cancer cells), and a custom mRNA vaccine encoding those neoantigens is manufactured in approximately six weeks. Moderna's AI-driven sequencing and antigen selection platform, developed in partnership with Microsoft Research's Project Hanover, identifies which neoantigens are most likely to generate a T-cell response, dramatically improving on earlier manual curation approaches.

The manufacturing process leverages the same lipid nanoparticle and mRNA synthesis platform used for Moderna's COVID-19 vaccine, providing a regulatory and manufacturing pathway that is faster and more scalable than traditional personalized medicine approaches like CAR-T cell therapy.

⚙️ Market Reaction and Pipeline Implications

Moderna shares (NASDAQ: MRNA) rose 18% on the day of the announcement, adding approximately $14 billion in market capitalization, while the NASDAQ Biotechnology Index (NBI) gained 4.2% — its largest single-day move since the initial COVID-19 vaccine efficacy readouts in November 2020. The rally reflected a broader reassessment of mRNA's therapeutic potential. Before the melanoma readout, investor consensus had valued Moderna primarily as a respiratory vaccine company with a declining COVID-19 market.

The Phase 3 oncology data established a credible second franchise potentially larger than vaccines.

Moderna currently has five personalized cancer vaccine programs in late-stage trials: melanoma (Phase 3), non-small cell lung cancer (Phase 3, enrolling), colorectal cancer (Phase 2), pancreatic cancer (Phase 2), and urothelial carcinoma (Phase 2). The company projects an annual oncology revenue opportunity of $15-25 billion by 2030, based on an estimated 850,000 addressable patients per year across all solid tumor indications at an assumed $100,000-150,000 per treatment course price.

BioNTech has a competing personalized cancer vaccine platform (BNT122) in Phase 2 trials, and CureVac is pursuing a similar approach, making this a three-way mRNA oncology race.